<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579253</url>
  </required_header>
  <id_info>
    <org_study_id>361-11</org_study_id>
    <nct_id>NCT01579253</nct_id>
  </id_info>
  <brief_title>Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients</brief_title>
  <official_title>Untersuchungen Zur Verlaufskontrolle Bei Re-Bestrahlung Von Glioblastompatienten Mittels Kombinierter [18F]FET-PET-Kernspintomographie</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with recurrent glioblastoma who are planned to receive a second course of radiation&#xD;
      are to be included into this monocentric cohort trial. Due to multiple pre-treatments&#xD;
      simultaneous combined positron emission tomography (PET) with&#xD;
      O-(2-[18F]fluoroethyl)-l-tyrosine (FET) as well as magnetic resonance imaging (MRI) is used&#xD;
      for treatment planning and follow-up imaging as it allows for a better distinction between&#xD;
      treatment-related changes and viable tumor tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For glioblastoma (GBM) patients it has been proven that a [18F]FET-PET scan is very helpful&#xD;
      especially in target volume definition and after the treatment, in turn, the combination of&#xD;
      MRI and [18F]FET-PET is diagnostically most useful to distinguish between radiation necrosis&#xD;
      and a real progressive disease.&#xD;
&#xD;
      The response to therapy is based on the newly formulated Revised Assessment in Neuro-Oncology&#xD;
      (RANO) criteria. Kinetic and static [18F]FET-PET scans are useful to supplement this modality&#xD;
      and its own prognostic value concerning relapsing patients will be examined.&#xD;
&#xD;
      The special feature of this study is the use of both modalities in parallel, allowing&#xD;
      simultaneous acquisition of morphological changes, functional and molecular imaging.&#xD;
&#xD;
      Secondary methodological issues are dealt with, such as the relationship between contrast&#xD;
      uptake, perfusion and [18F]FET uptake. In this regard, the hybrid imaging may serve for&#xD;
      hypothesis generation, as in parallel in a unique way of contrast enhancement and tracer&#xD;
      kinetics can be investigated (simultaneous contrast-enhanced analysis and tracer&#xD;
      application).&#xD;
&#xD;
      In particular, FET kinetics are examined in more detail (for example, differences between&#xD;
      increasing and decreasing kinetics) to find ways of how to use certain MRI sequences for&#xD;
      better visualization of viable tumor tissue and vice versa .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Nervous System Neoplasms</condition>
  <condition>Central Nervous System Neoplasms</condition>
  <condition>Astrocytoma</condition>
  <condition>Glioma</condition>
  <condition>Neoplasms, Neuroepithelial</condition>
  <condition>Neuroectodermal Tumors</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Neoplasms, Nerve Tissue</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recurrent glioblastoma who are planned to receive a re-irradiation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 75 years old&#xD;
&#xD;
          -  histologically or magnetic resonance imaging proven recurrent glioblastoma&#xD;
&#xD;
          -  re-irradiation possible&#xD;
&#xD;
          -  willing and able to give free informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not willing or able to give free informed consent&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  metallic objects or implanted medical devices in the body&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maximilian Niyazi, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maximilian Niyazi, MD, MSc</last_name>
    <phone>00498970953770</phone>
    <email>Maximilian.Niyazi@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Munich, Dep. of Radiation Oncology</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maximilian Niyazi, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>April 15, 2012</study_first_submitted>
  <study_first_submitted_qc>April 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Dr. med. Dipl.-Phys. Maximilian Niyazi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Recurrent glioblastoma</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>PET-MRI</keyword>
  <keyword>FET-PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Neoplasms, Neuroepithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

